A recent study conducted in collaboration with the National Institute of Virology and the Indian Council of Medical Research has demonstrated that the Covaxin vaccine could protect against the new SARS-CoV-2 variants.
The study which is now published in the journal Clinical Infectious Diseases found that vaccination with Covaxin produced neutralising antibody titres against all key emerging variants tested including B.1.617 and B.1.1.7, first identified in India and the UK, respectively.
A modest reduction in neutralisation by a factor of 1.95 was observed against B.1.617 variant compared to the vaccine variant (D614G). Despite this reduction, neutralising titre levels with B.1.617 remained above levels expected to be protective. No difference in neutralisation between B.1.1.7 and D614G was observed, noted the study.